BCL2 and acute myeloid leukemia: As expected, the selective BCL2 inhibitor VEN could not synergize with UNBS1450 in M6 AML, in line with our previous findings [17] and K562 cells (Fig. 4D–G, Supplementary Figs. S9D, E, S10).